For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?
A dramatic extension in progression-free survival in Astrazeneca's Solo-1 study raises the prospect of improving cure rates in ovarian cancer, though the impact…
Response rates in BRCA-positive patients hint at Parp inhibitors’ potential in prostate cancer, but Clovis reins in hopes for a different genetic marker.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.